Literature DB >> 9407956

Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice.

L W Wattenberg1, T S Wiedmann, R D Estensen, C L Zimmerman, V E Steele, G J Kelloff.   

Abstract

This investigation is part of a continuing effort to develop effective chemoprevention for carcinogenesis of the lung. The present study explores the use of aerosol administrations for this purpose. The agent selected for initial study was the synthetic glucocorticoid budesonide. This selection was based on previous work in which budesonide added to the diet was found to inhibit pulmonary adenoma formation in female A/J mice. However, high dose levels were required, i.e., of the order of 300 microg/kg, of body weight [L. W. Wattenberg and R. D. Estensen, Carcinogenesis (Lond.), 18: 2015-2017, 1997]. For aerosol administration of budesonide, a nose-only technique has been developed that entails nebulization of the compound dissolved in ethanol and subsequent stripping off of the solvent (less than 3 microl ethanol/liter of air remaining at the site of inhalation). The budesonide particles produced by the apparatus had a mass median aerodynamic diameter of less than 1 microm. An experiment has been carried out in which the inhibitory effects of aerosolized budesonide, given for 1 min six times a week, were studied. Concentrations of budesonide of 26, 81, and 148 microg/liter of air (calculated doses of 23, 72, and 126 microg/kg of body weight) were used. The aerosols were started 1 week after three oral administrations of benzo(a)pyrene (2 mg/20 g of body weight) to female A/J mice. All three doses of budesonide resulted in more than 80% inhibition of pulmonary tumor formation compared to the aerosol control and 90% or greater compared to mice not exposed to aerosol. The difference in inhibition is due to the aerosol procedure itself, which produces a reduction in tumor formation. A decrease in splenic weight (evidence of a systemic effect) occurred at all doses of budesonide. To the best of our knowledge, this is the first published effort at the use of aerosol administration to prevent neoplasia of the respiratory tract. The results of the present study show that administration of a potential chemopreventive agent by aerosol at a low dose can inhibit the occurrence of pulmonary carcinogenesis in female A/J mice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9407956

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  25 in total

1.  Analysis of a diffusion dryer for the respiratory delivery of poorly water soluble drugs.

Authors:  S Pham; T S Wiedmann
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

2.  Chemopreventive efficacy and mechanism of licofelone in a mouse lung tumor model via aspiration.

Authors:  Sheela Sharma; Jin Lee; Jianliang Zhou; Vernon E Steele
Journal:  Cancer Prev Res (Phila)       Date:  2011-05-11

3.  Oral supplementation of piperine leads to altered phase II enzymes and reduced DNA damage and DNA-protein cross links in Benzo(a)pyrene induced experimental lung carcinogenesis.

Authors:  Karuppaiyah Selvendiran; Syed Mumtaz Banu; Dhanapal Sakthisekaran
Journal:  Mol Cell Biochem       Date:  2005-01       Impact factor: 3.396

4.  Applicability of an ultrasonic nebulization system for the airways delivery of beclomethasone dipropionate in a murine model of asthma.

Authors:  Boska Hrvacić; Berislav Bosnjak; Marijan Tudja; Milan Mesić; Mladen Merćep
Journal:  Pharm Res       Date:  2006-08       Impact factor: 4.200

5.  The use of animal models for cancer chemoprevention drug development.

Authors:  Vernon E Steele; Ronald A Lubet
Journal:  Semin Oncol       Date:  2010-08       Impact factor: 4.929

6.  Modulation of microRNA expression by budesonide, phenethyl isothiocyanate and cigarette smoke in mouse liver and lung.

Authors:  Alberto Izzotti; Patrizia Larghero; Cristina Cartiglia; Mariagrazia Longobardi; Ulrich Pfeffer; Vernon E Steele; Silvio De Flora
Journal:  Carcinogenesis       Date:  2010-02-09       Impact factor: 4.944

7.  Progression of airway dysplasia and C-reactive protein in smokers at high risk of lung cancer.

Authors:  Don D Sin; S F Paul Man; Annette McWilliams; Stephen Lam
Journal:  Am J Respir Crit Care Med       Date:  2005-12-09       Impact factor: 21.405

8.  Inhaled corticosteroids and risk of lung cancer among patients with chronic obstructive pulmonary disease.

Authors:  Tanyalak Parimon; Jason W Chien; Chris L Bryson; Mary B McDonell; Edmunds M Udris; David H Au
Journal:  Am J Respir Crit Care Med       Date:  2006-12-21       Impact factor: 21.405

9.  REV1 is implicated in the development of carcinogen-induced lung cancer.

Authors:  Chad A Dumstorf; Suparna Mukhopadhyay; Elangovan Krishnan; Bodduluri Haribabu; W Glenn McGregor
Journal:  Mol Cancer Res       Date:  2009-01-27       Impact factor: 5.852

10.  Preventive effects of bexarotene and budesonide in a genetically engineered mouse model of small cell lung cancer.

Authors:  Yian Wang; Weidong Wen; Yijun Yi; Zhongqiu Zhang; Ronald A Lubet; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2009-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.